Open this publication in new window or tab >>Erasmus School of Health Policy & Management, Erasmus University, Rotterdam, the Netherlands;Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
Université de Paris, CRESS, INSERM, INRA, URCEco, AP-HP, Hôpital de l'Hôtel Dieu, Paris, France.
Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, the Netherlands.
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Society and Health. Linköping University, Faculty of Medicine and Health Sciences.
Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
Institute of Pathology, University Hospital Cologne, Germany.
Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada;Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada;Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Centre for Cancer Research, University of Melbourne, Melbourne, Australia.
Cancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
Institut Gustave Roussy, Villejuif, France.
Stichting Lygature, Utrecht, the Netherlands.
Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain;Centro de Investigación Biomédica en Red, Cáncer (CIBERONC), Madrid, Spain;Hematopathology Unit, Hospital Clínic of Barcelona, Barcelona, Spain;University of Barcelona, Barcelona, Spain.
Hartwig Medical Foundation, Amsterdam, the Netherlands.
University of Oxford, Oxford, United Kingdom.
Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Berlin Institute of Health at Charité—Universitätsmedizin Berlin, Clinical Study Center, Berlin, Germany.
Munich Leukemia Laboratory, Munich, Germany.
Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany.
New York Genome Center; Department of Pathology, Columbia University Irving Medical Center, New York, NY.
Show others...
2022 (English)In: JCO Precision Oncology, E-ISSN 2473-4284, Vol. 6, article id e2200245Article in journal (Refereed) Published
Abstract [en]
PURPOSE The combination of whole-genome and transcriptome sequencing (WGTS) is expected to transformdiagnosis and treatment for patients with cancer. WGTS is a comprehensive precision diagnostic test that isstarting to replace the standard of care for oncology molecular testing in health care systems around the world;however, the implementation and widescale adoption of this best-in-class testing is lacking.
METHODS Here, we address the barriers in integrating WGTS for cancer diagnostics and treatment selection andanswer questions regarding utility in different cancer types, cost-effectiveness and affordability, and otherpractical considerations for WGTS implementation.
RESULTS We review the current studies implementing WGTS in health care systems and provide a synopsis of theclinical evidence and insights into practical considerations for WGTS implementation. We reflect on regulatory,costs, reimbursement, and incidental findings aspects of this test.
CONCLUSION WGTS is an appropriate comprehensive clinical test for many tumor types and can replacemultiple, cascade testing approaches currently performed. Decreasing sequencing cost, increasing number ofclinically relevant aberrations and discovery of more complex biomarkers of treatment response, should pave theway for health care systems and laboratories in implementing WGTS into clinical practice, to transform diagnosisand treatment for patients with cancer.
Place, publisher, year, edition, pages
American Society of Clinical Oncology, 2022
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-193342 (URN)10.1200/po.22.00245 (DOI)000975488400088 ()36480778 (PubMedID)
Note
Funding agencies: Hartwig Medical Foundation (Hans van Snellenberg, Edwin Cuppen)receives funding from Hartwig Foundation, the Dutch Cancer Foundation(KWF), ZonMW and Illumina Inc. R.R. received funding from the SwedishCancer Society, the Swedish Research Council, the Knut and AliceWallenberg Foundation, Karolinska Institutet, Karolinska UniversityHospital, and Radiumhemmets Forskningsfonder, Stockholm. Universityof Twente, Enschede, The Netherlands (M.I.) receives funding fromIllumina Inc. C.G.M. is supported by NCI CA 197695. S.F. receivedsupport from the National Center for Tumor Diseases and the German Cancer Consortium. C.C. is supported by funding from CRUK (grantnumbers A17197, A27657 and A29580) and a European ResearchCouncil Advanced Award (grant number 694620). T.J.P. holds theCanada Research Chair in Translational Genomics and is supported by aSenior Investigator Award from the Ontario Institute for Cancer Researchand the Gattuso-Slaight Personalized Cancer Medicine Fund.
2023-05-022023-05-022023-08-21